NCT06794099

Study on the Applicability of CCR Criteria in Rectal Cancer

Applicability of CCR Assessment Criteria in PMMR Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy Combined with Immunotherapy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 177 (actual)
• Sponsor: Peking University Cancer Hospital & Institute · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study aims to explore how well the usual ways of checking if rectal cancer patients are free of disease signs after treatment work for a new treatment method. The new method combines chemotherapy, radiation, and immune-boosting drugs before surgery. We know these usual ways work for the standard treatment, but we're not sure if they're good enough for this new combo treatment. We'll look at patients with a specific type of rectal cancer that doesn't respond well to just immune-boosting drugs alone. By comparing how patients treated with the new method and the old method respond, we hope to find better ways to tell if the treatment is really working, which could help improve treatment plans for these patients.

Conditions

• PMMR/MSS Adenocarcinoma of the Colon or Rectum
• Neoadjuvant Chemoradiotherapy
• Immunotherapy
• Complete Response

Timeline

• Start date: 2019-01-01
• Primary completion: 2024-10-01
• Completion: 2025-01-01
• First posted: 2025-01-27
• Last updated: 2025-01-27

Locations

1 site across 1 country: China